Capital International Investors Zentalis Pharmaceuticals, Inc. Transaction History

Capital International Investors

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$4.09 - $16.13 $8.77 Million - $34.6 Million	-2,144,293 Reduced 76.05%	675,371 $2.76 Million
Q4 2023 Feb 13, 2024	SELL	$9.84 - $20.13 $3.03 Million - $6.2 Million	-308,094 Reduced 9.85%	2,819,664 $42.7 Million
Q1 2023 May 15, 2023	BUY	$16.14 - $24.94 $1.28 Million - $1.98 Million	79,576 Added 2.61%	3,127,758 $53.8 Million
Q4 2022 Feb 14, 2023	BUY	$18.07 - $25.6 $55.1 Million - $78 Million	3,048,182 New	3,048,182 $61.4 Million

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

Stay updated on Capital International Investors with notifications on news.